MTOR and neoplasm: This gives rationale to a druggability of EEF1A2-dependent tumor growth in PCa with mTOR inhibitors, which are already in clinical use e.g. for metastatic renal cell carcinoma, breast cancer, neuroendocrine tumors and certain lymphomas [26, 27].